Mission possible

  title={Mission possible},
  author={Andrew L. Hopkins and Michael J Witty and Solomon Nwaka},
ew drugs are urgently needed for neglected tropical diseases and tuberculosis. Although one person in six suffers from such diseases, the few drugs available are not widely used, owing to problems with safety, administration, cost and — increasingly — resistance of the infectious agents. Moreover, there is a shortage of potential drugs for these diseases. So how do we meet this challenge and accelerate the flow of drugs through the pipeline? The dearth of new drugs entering development for… 
Innovative Partnerships for Drug Discovery against Neglected Diseases
In the absence of a perceived commercial market for drugs against neglected diseases, it is critical to devise sustainable approaches to stimulate and fund R&D activities in this field, including a more coordinated collaboration mechanism involving multidisciplinary networks of investigators and partnerships between industry and public sector.
Expert Delphi survey on research and development into drugs for neglected diseases
While not all features of orphan drug regulations and of the MRDT draft received equal support, the view was expressed that a regulatory instrument would be a desirable and feasible measure to promote R&D for neglected diseases.
Structure-based drug discovery for tropical diseases.
This review presents the current progresses and applications of structure-based drug design (SBDD) for the discovery of innovative chemotherapy agents for a variety of parasitic diseases, highlighting the challenges, limitations, and future perspectives in medicinal chemistry.
The challenges of developing novel antiparasitic drugs
The rapid progression of genomics has unlocked a plethora of tools for target identification, validation and screening, revolutionising mechanism-based screening for antiparasitic drug discovery, but the challenge still remains to identify novel chemical entities with the properties required to deliver a safe, effective antiparAsitic drug.
Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression
New opportunities and challenges are highlighted through the virtual North–South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation.
A Kernel for Open Source Drug Discovery in Tropical Diseases
The TDI kernel provides a source of potential drug targets and drug candidates around which an online open source community can nucleate and will facilitate collaborative efforts towards the discovery of new drugs against parasites that cause tropical diseases.
Miltefosine, a promising novel agent for schistosomiasis mansoni.
Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development
  • K. Seifert
  • Medicine, Biology
    The open medicinal chemistry journal
  • 2011
A brief overview of recent developments and approaches in anti-leishmanial drug discovery and development is given.
Phenotypic and molecular analysis of desensitization to levamisole in male and female adult Brugia malayi
The issues of anthelmintic resistance in vitro are investigated using Worminator, which quantitatively measures the motility of B. malayi and qRT-PCR (quantitative real time polymerase chain reaction) to analysis the relative expression changes of nAChR subunit mRNAs.
The hope for neglected diseases: R&D incentives
Neglected diseases are neglected because they cannot generate enough return on R&D to pharmaceutical firms. This paper analyzes and compares existing proposals for public intervention in R&D for


Open Business Models: How to Thrive in the New Innovation Landscape
In his landmark book Open Innovation, Henry Chesbrough demonstrated that because useful knowledge is no longer concentrated in a few large organizations, business leaders must adopt a new, "open"